Trial Profile

Phase 2 Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 08 Aug 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Eganelisib (Primary)
Indications Head and neck cancer; Squamous cell cancer
Focus Adverse reactions; Biomarker; Pharmacodynamics

Most Recent Events

25 Jul 2025 Status changed from recruiting to completed.
20 Jul 2022 Planned primary completion date changed from 1 Jun 2022 to 1 Jun 2023.
29 Mar 2022 According to an Infinity Pharmaceutical media release, additional data from this study will be release in 2H 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com